Brief: Y-Mabs Announces Second Quarter Financial Results And Recent Corporate Developments

Y-mAbs Therapeutics

08/08/2022 23:27

Aug 8 (Reuters) - Y-mAbs Therapeutics Inc  YMAB.O :
    * Y-MABS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS AND
RECENT
CORPORATE DEVELOPMENTS
    * OMBURTAMAB BLA ACCEPTED BY FDA WITH NOVEMBER 2022 PDUFA
DATE
    * REITERATES FINANCIAL GUIDANCE, INCLUDING 2022 FULL-YEAR
DANYELZA® REVENUE OF $45-$50 MILLION
    * ANNOUNCED IND CLEARANCE FOR FIRST GD2-SADA CONSTRUCT
    * STRONG CASH POSITION WITH $133.7 MILLION AS OF JUNE 30,
2022,
ANTICIPATED RUNWAY INTO MID-2024
    * QTRLY LOSS PER SHARE $0.94
    * Q2 EARNINGS PER SHARE VIEW $-0.67 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX3JdLNW 
Further company coverage:  YMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))